Abstract
Gammagard ®* has been used in the United Kingdom to prevent bacterial infections in patients with primary and secondary antibody deficiencies since the initial clinical trial in patients with chronic lymphocytic leukemia in 1984.1 Routine monitoring of liver function tests before any intravenous immunoglobulin (IGIV) is administered and at regular intervals (usually every 3 to 6 weeks) has been the policy of clinical immunologists in the United Kingdom. 2 Outbreaks of hepatitis C virus (HCV) in the United Kingdom, 3,4 as well as elsewhere in Europe and the United States, ensured that such monitoring was widespread. The first abnormal liver function tests in patients receiving IGIV encountered in our center in more than 10 years were
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
